Search

Your search keyword '"Santesmases, Javier"' showing total 159 results
Start Over Author "Santesmases, Javier"
159 results on '"Santesmases, Javier"'

17. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension

Author

Codina, Pau, primary, Domingo, Mar, additional, Barceló, Elena, additional, Gastelurrutia, Paloma, additional, Casquete, Daniel, additional, Vila, Joan, additional, Abdul‐Jawad Altisent, Omar, additional, Spitaleri, Giosafat, additional, Cediel, Germán, additional, Santiago‐Vacas, Evelyn, additional, Zamora, Elisabet, additional, Ruiz‐Cueto, María, additional, Santesmases, Javier, additional, de la Espriella, Rafael, additional, Pascual‐Figal, Domingo A., additional, Nuñez, Julio, additional, Lupón, Josep, additional, and Bayes‐Genis, Antoni, additional

Published
2022
Full Text
View/download PDF

18. Cause of Death in Heart Failure Based on Etiology : Long-Term Cohort Study of All-Cause and Cardiovascular Mortality

Author

Spitaleri, Giosafat, Zamora, Elisabet, Cediel, Germán, Codina, Pau, Santiago-Vacas, Evelyn, Domingo, Mar, Lupón, Josep, Santesmases, Javier, Diez-Quevedo, Crisanto, Troya, Maria Isabel, Boldo, Maria, Altimir, Salvador, Alonso, Núria, González, Beatriz, Bayes-Genis, Antoni, Spitaleri, Giosafat, Zamora, Elisabet, Cediel, Germán, Codina, Pau, Santiago-Vacas, Evelyn, Domingo, Mar, Lupón, Josep, Santesmases, Javier, Diez-Quevedo, Crisanto, Troya, Maria Isabel, Boldo, Maria, Altimir, Salvador, Alonso, Núria, González, Beatriz, and Bayes-Genis, Antoni

Abstract

We assessed differences in long-term all-cause and cardiovascular (CV) mortality in heart failure (HF) outpatients based on the etiology of HF. Consecutive patients admitted to the HF Clinic from August 2001 to September 2019 (N = 2587) were considered for inclusion. HF etiology was divided into ischemic heart disease (IHD), dilated cardiomyopathy (DCM), hypertensive heart disease, alcoholic cardiomyopathy, drug-induced cardiomyopathy (DICM), valvular heart disease, and hypertrophic cardiomyopathy. All-cause death and CV death were the primary end points. Among 2387 patients included in the analysis (mean age 66.5 ± 12.5 years, 71.3% men), 1317 deaths were recorded (731 from CV cause) over a maximum follow-up of 18 years (median 4.1 years, interquartile range (IQR) 2-7.8). Considering IHD as the reference, only DCM had a lower risk of all-cause death (adjusted hazard ratio (aHR) 0.68, 95% confidence interval (CI) 0.56-0.83, p < 0.001), and only DICM had a higher risk of all-cause death (aHR 1.47, 95% CI 1.02-2.11, p = 0.04). However, almost all etiologies had a significantly lower risk of CV death than IHD. Among the studied HF etiologies, DCM and DICM have the lowest and highest risk of all-cause death, respectively, whereas IHD has the highest adjusted risk of CV death.

Published
2022

19. Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators

Author

Codina, Pau, primary, Zamora, Elisabet, additional, Levy, Wayne C., additional, Revuelta-López, Elena, additional, Borrellas, Andrea, additional, Spitaleri, Giosafat, additional, Cediel, Germán, additional, Ruiz-Cueto, María, additional, Cañedo, Elena, additional, Santiago-Vacas, Evelyn, additional, Domingo, Mar, additional, Buchaca, David, additional, Subirana, Isaac, additional, Santesmases, Javier, additional, Espriella, Rafael de la, additional, Nuñez, Julio, additional, Lupón, Josep, additional, and Bayes-Genis, Antoni, additional

Published
2022
Full Text
View/download PDF

20. Head‐to‐head comparison of contemporary heart failure risk scores

Author

Codina, Pau, Lupón, Josep, Borrellas, Andrea, Spitaleri, Giosafat, Cediel, Germán, Domingo, Mar, Simpson, Joanne, Levy, Wayne C., Santiago‐Vacas, Evelyn, Zamora, Elisabet, Buchaca, David, Subirana, Isaac, Santesmases, Javier, Diez‐Quevedo, Crisanto, Troya, Maria I., Boldo, Maria, Altmir, Salvador, Alonso, Nuria, González, Beatriz, Rivas, Carmen, Nuñez, Julio, McMurray, John, and Bayes‐Genis, Antoni

Abstract

Aims: \ud Several heart failure (HF) web-based risk scores are currently used in clinical practice. Currently, we lack head-to-head comparison of the accuracy of risk scores. This study aimed to assess correlation and mortality prediction performance of Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC-HF) risk score, which includes clinical variables + medications; Seattle Heart Failure Model (SHFM), which includes clinical variables + treatments + analytes; PARADIGM Risk of Events and Death in the Contemporary Treatment of Heart Failure (PREDICT-HF) and Barcelona Bio-Heart Failure (BCN-Bio-HF) risk calculator, which also include biomarkers, like N-terminal pro B-type natriuretic peptide (NT-proBNP).\ud \ud Methods and results: \ud A total of 1166 consecutive patients with HF from different aetiologies that had NT-proBNP measurement at first visit were included. Discrimination for all-cause mortality was compared by Harrell's C-statistic from 1 to 5 years, when possible. Calibration was assessed by calibration plots and Hosmer–Lemeshow test and global performance by Nagelkerke's R2. Correlation between scores was assessed by Spearman rank test. Correlation between the scores was relatively poor (rho value from 0.66 to 0.79). Discrimination analyses showed better results for 1-year mortality than for longer follow-up (SHFM 0.817, MAGGIC-HF 0.801, PREDICT-HF 0.799, BCN-Bio-HF 0.830). MAGGIC-HF showed the best calibration, BCN-Bio-HF overestimated risk while SHFM and PREDICT-HF underestimated it. BCN-Bio-HF provided the best discrimination and overall performance at every time-point.\ud \ud Conclusions: \ud None of the contemporary risk scores examined showed a clear superiority over the rest. BCN-Bio-HF calculator provided the best discrimination and overall performance with overestimation of risk. MAGGIC-HF showed the best calibration, and SHFM and PREDICT-HF tended to underestimate risk. Regular updating and recalibration of online web calculators seems necessary to improve their accuracy as HF management evolves at unprecedented pace.

Published
2021

21. Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality

Author

Spitaleri, Giosafat, primary, Zamora, Elisabet, additional, Cediel, German, additional, Codina, Pau, additional, Santiago-Vacas, Evelyn, additional, Domingo, Mar, additional, Lupón, Josep, additional, Santesmases, Javier, additional, Diez-Quevedo, Crisanto, additional, Troya, Maria Isabel, additional, Boldo, Maria, additional, Altimir, Salvador, additional, Alonso, Núria, additional, González, Beatriz, additional, and Bayes-Genis, Antoni, additional

Published
2022
Full Text
View/download PDF

22. Global Warming, Renal Function and Heart Failure Over 20 Years

Author

Aimo, Alberto, primary, Lupon, Josep, additional, Spitaleri, Giosafat, additional, Domingo, Mar, additional, Codina, Pau, additional, Santiago-Vacas, Evelyin, additional, Cediel, German, additional, Zamora, Elizabet, additional, Troya, Maribel, additional, Santesmases, Javier, additional, Romero-Gonzalez, Gregorio A., additional, Nuñez, Julio, additional, Martini, Nicola, additional, Emdin, Michele, additional, and Bayes-Genis, Antoni, additional

Published
2022
Full Text
View/download PDF

23. Prognostic value of lung ultrasound in chronic stable ambulatory heart failure patients

Author

Domingo, Mar, primary, Conangla, Laura, additional, Lupón, Josep, additional, de Antonio, Marta, additional, Moliner, Pedro, additional, Santiago-Vacas, Evelyn, additional, Codina, Pau, additional, Zamora, Elisabet, additional, Cediel, Germán, additional, González, Beatriz, additional, Díaz, Violeta, additional, Rivas, Carmen, additional, Velayos, Patricia, additional, Santesmases, Javier, additional, Pulido, Ana, additional, Crespo, Eva, additional, and Bayés-Genís, Antoni, additional

Published
2021
Full Text
View/download PDF

25. Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?

Author

Lupón, Josep, primary, Santiago-Vacas, Evelyn, additional, Cediel, Germán, additional, Codina, Pau, additional, Domingo, Mar, additional, Revuelta-López, Elena, additional, Zamora, Elisabet, additional, Spitaleri, Giosafat, additional, Santesmases, Javier, additional, Núñez, Julio, additional, and Bayes-Genis, Antoni, additional

Published
2021
Full Text
View/download PDF

26. Additional file 2 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline

Author

Julián, María Teresa, Alonso, Núria, Lupón, Josep, Giovana Gavidia-Bovadilla, Ferrer, Elena, Antonio, Marta De, López-Ayerbe, Jorge, Domingo, Mar, Santiago-Vacas, Evelyn, Zamora, Elisabet, Codina, Pau, Moliner, Pedro, Núñez, Julio, Santesmases, Javier, Puig-Domingo, Manel, and Bayes-Genis, Antoni

Abstract

Additional file 2: Table S1. Demographic, clinical, and therapeutic characteristics at baseline and treatments during follow-up according to etiology of heart failure and presence of diabetes mellitus. Table S2. Paired wise means data analysis in diabetic patients. Table S3. Causes of death of the studied cohort during the 15-year follow-up, according the presence or absence of diabetes mellitus. Table S4. Multivariable Cox regression analysis for all-cause death and the composite end-point all-cause death or heart failure hospitalization.

Published
2020
Full Text
View/download PDF

27. Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15‐year prospective longitudinal trajectories in survivors

Author

Santiago‐Vacas, Evelyn, primary, Lupón, Josep, additional, Gavidia‐Bovadilla, Giovana, additional, Gual‐Capllonch, Francisco, additional, Antonio, Marta, additional, Domingo, Mar, additional, Núñez, Julio, additional, Zamora, Elisabet, additional, Teis, Albert, additional, Moliner, Pedro, additional, Codina, Pau, additional, Santesmases, Javier, additional, and Bayes‐Genis, Antoni, additional

Published
2020
Full Text
View/download PDF

30. Additional file 2: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

Author

Pacho, Cristina, Domingo, Mar, Núñez, Raquel, Lupón, Josep, Núñez, Julio, Barallat, Jaume, Moliner, Pedro, Antonio, Marta De, Santesmases, Javier, Cediel, Germán, Roura, Santiago, M. Pastor, Tor, Jordi, and Bayes-Genis, Antoni

Abstract

Table S2. Cox regression analyses for 30-day rehospitalization. A competing risk strategy using the Gray method was adopted, considering death as the competing risk in both univariate and multivariate Cox regression analyses. (DOCX 27 kb)

Published
2018
Full Text
View/download PDF

31. Additional file 3: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

Author

Pacho, Cristina, Domingo, Mar, Núñez, Raquel, Lupón, Josep, Núñez, Julio, Barallat, Jaume, Moliner, Pedro, Antonio, Marta De, Santesmases, Javier, Cediel, Germán, Roura, Santiago, M. Pastor, Tor, Jordi, and Bayes-Genis, Antoni

Abstract

Table S3. Cox regression analyses for 1-year HF-related hospitalization. A competing risk strategy using the Gray method was adopted, considering death as the competing risk in both univariate and multivariate Cox regression analyses. (DOCX 27 kb)

Published
2018
Full Text
View/download PDF

32. Additional file 1: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

Author

Pacho, Cristina, Domingo, Mar, Núñez, Raquel, Lupón, Josep, Núñez, Julio, Barallat, Jaume, Moliner, Pedro, Antonio, Marta De, Santesmases, Javier, Cediel, Germán, Roura, Santiago, M. Pastor, Tor, Jordi, and Bayes-Genis, Antoni

Abstract

Table S1. Correlations between studied biomarkers. Correlation between the different studied biomarkers was performed using Pearson correlation test of log-transformed values of each biomarker. (DOCX 25 kb)

Published
2018
Full Text
View/download PDF

33. A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score

Author

Lupón, Josep, primary, Cediel, Germán, additional, Moliner, Pedro, additional, de Antonio, Marta, additional, Domingo, Mar, additional, Zamora, Elisabet, additional, Núñez, Julio, additional, González, Beatriz, additional, Santiago-Vacas, Evelyn, additional, Santesmases, Javier, additional, Troya, Maria Isabel, additional, Díez-Quevedo, Crisanto, additional, Boldó, Maria, additional, Barallat, Jaume, additional, and Bayes-Genis, Antoni, additional

Published
2019
Full Text
View/download PDF

34. Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise

Author

Moliner, Pedro, primary, Lupón, Josep, additional, Antonio, Marta, additional, Domingo, Mar, additional, Santiago‐Vacas, Evelyn, additional, Zamora, Elisabet, additional, Cediel, Germán, additional, Santesmases, Javier, additional, Díez‐Quevedo, Crisanto, additional, Troya, Maria Isabel, additional, Boldó, Maria, additional, Altmir, Salvador, additional, Alonso, Nuria, additional, González, Beatriz, additional, Núñez, Julio, additional, and Bayes‐Genis, Antoni, additional

Published
2019
Full Text
View/download PDF

35. Una consulta específica al alta ( STOP-HF-Clinic ) reduce los reingresos a 30 días de los pacientes ancianos y frágiles con insuficiencia cardiaca

Author

Pacho, Cristina, primary, Domingo, Mar, additional, Núñez, Raquel, additional, Lupón, Josep, additional, Moliner, Pedro, additional, de Antonio, Marta, additional, González, Beatriz, additional, Santesmases, Javier, additional, Vela, Emili, additional, Tor, Jordi, additional, and Bayes-Genis, Antoni, additional

Published
2017
Full Text
View/download PDF

36. Impact of diabetes on the predictive value of heart failure biomarkers

Author

Alonso, Nuria, primary, Lupón, Josep, additional, Barallat, Jaume, additional, de Antonio, Marta, additional, Domingo, Mar, additional, Zamora, Elisabet, additional, Moliner, Pedro, additional, Galán, Amparo, additional, Santesmases, Javier, additional, Pastor, Cruz, additional, Mauricio, Dídac, additional, and Bayes-Genis, Antoni, additional

Published
2016
Full Text
View/download PDF

38. No benefit from the obesity paradox for diabetic patients with heart failure

Author

Zamora, Elisabet, primary, Lupón, Josep, additional, Enjuanes, Cristina, additional, Pascual-Figal, Domingo, additional, de Antonio, Marta, additional, Domingo, Mar, additional, Comín-Colet, Josep, additional, Vila, Joan, additional, Peñafiel, Judith, additional, Farré, Núria, additional, Alonso, Núria, additional, Santesmases, Javier, additional, Troya, Maribel, additional, and Bayés-Genís, Antoni, additional

Published
2016
Full Text
View/download PDF

39. Weight Loss in Obese Patients With Heart Failure

Author

Zamora, Elisabet, primary, Díez‐López, Carles, additional, Lupón, Josep, additional, de Antonio, Marta, additional, Domingo, Mar, additional, Santesmases, Javier, additional, Troya, María Isabel, additional, Díez‐Quevedo, Crisanto, additional, Altimir, Salvador, additional, and Bayes‐Genis, Antoni, additional

Published
2016
Full Text
View/download PDF

46. Imagen de la semana

Author

Tapia, Gustavo, primary, Navarro, José-Tomás, additional, Santesmases, Javier, additional, and Capellades, Jaume, additional

Published
2005
Full Text
View/download PDF

48. Head-to-head comparison of contemporary heart failure risk scores.

Author

Codina P, Lupón J, Borrellas A, Spitaleri G, Cediel G, Domingo M, Simpson J, Levy WC, Santiago-Vacas E, Zamora E, Buchaca D, Subirana I, Santesmases J, Diez-Quevedo C, Troya MI, Boldo M, Altmir S, Alonso N, González B, Rivas C, Nuñez J, McMurray J, and Bayes-Genis A

Subjects
Biomarkers, Humans, Natriuretic Peptide, Brain, Natriuretic Peptides, Peptide Fragments, Prognosis, Risk Assessment methods, Risk Factors, Heart Failure diagnosis
Abstract

Aims: Several heart failure (HF) web-based risk scores are currently used in clinical practice. Currently, we lack head-to-head comparison of the accuracy of risk scores. This study aimed to assess correlation and mortality prediction performance of Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC-HF) risk score, which includes clinical variables + medications; Seattle Heart Failure Model (SHFM), which includes clinical variables + treatments + analytes; PARADIGM Risk of Events and Death in the Contemporary Treatment of Heart Failure (PREDICT-HF) and Barcelona Bio-Heart Failure (BCN-Bio-HF) risk calculator, which also include biomarkers, like N-terminal pro B-type natriuretic peptide (NT-proBNP)., Methods and Results: A total of 1166 consecutive patients with HF from different aetiologies that had NT-proBNP measurement at first visit were included. Discrimination for all-cause mortality was compared by Harrell's C-statistic from 1 to 5 years, when possible. Calibration was assessed by calibration plots and Hosmer-Lemeshow test and global performance by Nagelkerke's R 2 . Correlation between scores was assessed by Spearman rank test. Correlation between the scores was relatively poor (rho value from 0.66 to 0.79). Discrimination analyses showed better results for 1-year mortality than for longer follow-up (SHFM 0.817, MAGGIC-HF 0.801, PREDICT-HF 0.799, BCN-Bio-HF 0.830). MAGGIC-HF showed the best calibration, BCN-Bio-HF overestimated risk while SHFM and PREDICT-HF underestimated it. BCN-Bio-HF provided the best discrimination and overall performance at every time-point., Conclusions: None of the contemporary risk scores examined showed a clear superiority over the rest. BCN-Bio-HF calculator provided the best discrimination and overall performance with overestimation of risk. MAGGIC-HF showed the best calibration, and SHFM and PREDICT-HF tended to underestimate risk. Regular updating and recalibration of online web calculators seems necessary to improve their accuracy as HF management evolves at unprecedented pace., (© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2021
Full Text
View/download PDF

50. [Atrial fibrillation in elderly. That long way…].

Author

Urrutia A and Santesmases J

Subjects
Age Factors, Aged, Aged, 80 and over, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation drug therapy, Atrial Fibrillation economics, Cost of Illness, Hospitalization economics, Hospitalization statistics & numerical data, Humans, Prevalence, Spain epidemiology, Atrial Fibrillation epidemiology
Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results